TheraCode to Acquire JPT Peptide Technologies | GenomeWeb

NEW YORK (GenomeWeb News) - German-based TheraCode, a wholly owned subsidiary of biotech firm BioNTech, has announced its intentions to buy JPT Peptide Technologies, also based in Germany, for €5 million ($6.8 million) in an all-cash deal.

JPT had been a wholly owned subsidiary of Jerini, which sold the company as part of its strategy to divest non-strategic businesses and focus on its core business, the commercialization of the drug icatibant (Firazyr) for the treatment of hereditary angioedema.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Ivanka Trump and Secretary of Education Betsy DeVos call on girls to pursue STEM careers, the Associated Press reports.

Some science companies will be taking part in next month's March for Science, Fortune reports.

In Genome Research this week: longitudinal study of Burkholderia cenocepacia isolates from cystic fibrosis patients, long-read assembly approach, and more.

Shale oil companies are turning to DNA sequencing to find spots to drill, Reuters reports.